“While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration of growth for the quarter. That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results. We continued to make progress on our manufacturing build-out, and U.S. supply across all doses of tirzepatide was available throughout Q4,” said David A. Ricks, Lilly chair and CEO. “The rest of our medicines performed within our expectations.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) Expects Weight-Loss Pill Approval in 2026
- Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
- Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
- Verve Therapeutics announces anticipated 2025 milestones
- Potential acquisition of Scorpion positive for Relay, says Barclays